Form 4: Xeris Biopharma Holdings Director John P. Schmid Acquires Shares

Director John P. Schmid reports the acquisition of 4,285 shares of Xeris Biopharma Holdings, Inc. at a price of $2.365 per share on August 9, 2024.

Summary

• On August 9, 2024, John P. Schmid, a director of Xeris Biopharma Holdings, Inc., acquired 4,285 shares of common stock at $2.365 per share.
• The transaction increased Schmid's direct holdings to 113,159 shares.
• Schmid also indirectly owns 20,685 shares through The Schmid Family Trust dated August 15, 2017.
• He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, it's not overwhelmingly positive without additional context.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This specific transaction reflects the investment activity of a director in their own company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates